Ras interacting protein 1 facilitated proliferation and invasion of diffuse large B-cell lymphoma cells

References

• Sehn LH, Salles G, Longo DL. 2021. Diffuse large B-Cell Lymphoma. N Engl J Med. 384(9):842–13. doi:10.1056/NEJMra2027612. PMID:33657296.
   PubMed Web of Science ®Google Scholar
• Bakhshi TJ, Georgel PT. 2020. Genetic and epigenetic determinants of diffuse large B-cell lymphoma. Blood Cancer J. 10(12):123. doi:10.1038/s41408-020-00389-w. PMID:33277464.
   PubMed Web of Science ®Google Scholar
• Johnson NA, Boyle M, Bashashati A, Leach S, Brooks-Wilson A, Sehn LH, Chhanabhai M, Brinkman RR, Connors JM, Weng AP, et al. 2009. Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood. 113(16):3773–3780. doi:10.1182/blood-2008-09-177469. PMID:19029441
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, Shovlin M, Jaffe ES, Janik JE, Staudt LM, et al. 2009. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 113(24):6069–6076. doi:10.1182/blood-2009-01-199679. PMID:19380866
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al. 2000. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 403(6769):503–511. doi:10.1038/35000501. PMID:10676951
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, et al. 2002. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 346(25):1937–1947. doi:10.1056/NEJMoa012914. PMID:12075054
   PubMed Web of Science ®Google Scholar
• Natkunam Y, Farinha P, Hsi ED, Hans CP, Tibshirani R, Sehn LH, Connors JM, Gratzinger D, Rosado M, Zhao S, et al. 2008. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol. 26(3):447–454. doi:10.1200/JCO.2007.13.0690. PMID:18086797
   PubMed Web of Science ®Google Scholar
• Chen YW, Hu XT, Liang AC, Au WY, So CC, Wong ML, Shen L, Tao Q, Chu KM, Kwong YL, et al. 2006. High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric lymphoma. Blood. 108(7):2373–2383. doi:10.1182/blood-2006-05-022517. PMID:16772602
   PubMed Web of Science ®Google Scholar
• Wang D, Zhang Y, Che YQ. 2020. CCND2 mRNA expression is correlated with R-CHOP treatment efficacy and prognosis in patients with ABC-DLBCL. Front Oncol. 10(1180). doi:10.3389/fonc.2020.01180 PMID:32850340
   Google Scholar
• Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, Liu WM, Visco C, Li Y, Miranda RN, et al. 2013. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the international DLBCL Rituximab-CHOP Consortium program. Blood. 121(20):4021–31; quiz 4250. doi:10.1182/blood-2012-10-460063. PMID:23449635
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, et al. 2004. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 103(1):275–282. doi:10.1182/blood-2003-05-1545. PMID:14504078
   PubMed Web of Science ®Google Scholar
• Mitin NY, Ramocki MB, Zullo AJ, Der CJ, Konieczny SF, Taparowsky EJ. 2004. Identification and characterization of rain, a novel Ras-interacting protein with a unique subcellular localization. J Biol Chem. 279(21):22353–22361. doi:10.1074/jbc.M312867200. PMID:15031288.
   PubMed Web of Science ®Google Scholar
• Mitin N, Konieczny SF, Taparowsky EJ. 2006. RAS and the RAIN/RasIP1 effector. Methods Enzymol. 407(322–35). doi:10.1016/S0076-6879(05)07027-8 PMID:16757335
   PubMedGoogle Scholar
• Wilson CW, Parker LH, Hall CJ, Smyczek T, Mak J, Crow A, Posthuma G, De Maziere A, Sagolla M, Chalouni C, et al. 2013. Rasip1 regulates vertebrate vascular endothelial junction stability through Epac1-Rap1 signaling. Blood. 122(22):3678–3690. doi:10.1182/blood-2013-02-483156. PMID:23886837
   PubMed Web of Science ®Google Scholar
• Wilson CW, Ye W. 2014. Regulation of vascular endothelial junction stability and remodeling through Rap1-Rasip1 signaling. Cell Adhes Migr. 8(2):76–83. doi:10.4161/cam.28115. PMID:24622510.
   PubMed Web of Science ®Google Scholar
• Xu K, Sacharidou A, Fu S, Chong DC, Skaug B, Chen ZJ, Davis GE, Cleaver O. 2011. Blood vessel tubulogenesis requires Rasip1 regulation of GTPase signaling. Dev Cell. 20(4):526–539. PMID:21396893. doi:10.1016/j.devcel.2011.02.010.
   PubMed Web of Science ®Google Scholar
• Xu K, Chong DC, Rankin SA, Zorn AM, Cleaver O. 2009. Rasip1 is required for endothelial cell motility, angiogenesis and vessel formation. Dev Biol. 329(2):269–279MID:19272373. doi:10.1016/j.ydbio.2009.02.033.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang L, Liu L, Sun S, Zhao X, Wang Y, Zhang Y, Du J, Gu L. 2018. Rasip1 is a RUNX1 target gene and promotes migration of NSCLC cells. Cancer Manage Res. 10(4537):4537–4552. doi:10.2147/CMAR.S168438. PMID:30349386.
   PubMedGoogle Scholar
• Liu Y, Barta SK. 2019. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 94(5):604–616. doi:10.1002/ajh.25460. PMID:30859597.
   PubMed Web of Science ®Google Scholar
• Zheng X, Rui H, Liu Y, Dong J. 2020. Proliferation and Apoptosis of B-Cell Lymphoma cells under targeted regulation of FOXO3 by miR-155. Mediterr J Hematol Infect Dis. 12(1):e2020073. doi:10.4084/MJHID.2020.073. PMID:33194147.
   PubMedGoogle Scholar
• Eijkelenboom A, Mokry M, de Wit E, Smits LM, Polderman PE, van Triest MH, van Boxtel R, Schulze A, de Laat W, Cuppen E, et al. 2013. Genome-wide analysis of FOXO3 mediated transcription regulation through RNA polymerase II profiling. Mol Syst Biol. 9(1):638. doi:10.1038/msb.2012.74. PMID:23340844
   PubMed Web of Science ®Google Scholar
• Lee HY, Chung JW, Youn SW, Kim JY, Park KW, Koo BK, Oh BH, Park YB, Chaqour B, Walsh K, et al. 2007. Forkhead transcription factor FOXO3a is a negative regulator of angiogenic immediate early gene CYR61, leading to inhibition of vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ Res. 100(3):372–380. doi:10.1161/01.RES.0000257945.97958.77. PMID:17234971
   PubMed Web of Science ®Google Scholar
• Beckwith M, Longo DL, O’connell CD, Moratz CM, Urba WJ. 1990. Phorbol ester-induced, cell-cycle-specific, growth inhibition of human B-lymphoma cell lines. JNCI J Nat Cancer Inst. 82(6):501–509. doi:10.1093/jnci/82.6.501. PMID:2313723.
   PubMedGoogle Scholar
• Epstein AL, Herman MM, Kim H, Dorfman RF, Kaplan HS. 1976. Biology of the human malignant lymphomas. III. Intracranial heterotransplantation in the nude, athymic mouse. Cancer. 37(5):2158–2176. doi:10.1002/1097-014219760537:5<2158:aid-cncr2820370503>3.0.co;2-f. PMID:177185.
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. 2009. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 9(3):153–166. doi:10.1038/nrc2602. PMID:19238148.
   PubMed Web of Science ®Google Scholar
• Martinez-Alonso D, Malumbres M. 2020. Mammalian cell cycle cyclins. Semin Cell Dev Biol. 107(28):28–35. doi:10.1016/j.semcdb.2020.03.009. PMID:32334991.
   PubMedGoogle Scholar
• O’brien MA, Kirby R. 2008. Apoptosis: a review of pro-apoptotic and anti-apoptotic pathways and dysregulation in disease. J Vet Emerg Crit Care. 18(6):572–585. doi:10.1111/j.1476-4431.2008.00363.x.
   Web of Science ®Google Scholar
• Schneider P, Tschopp J. 2000. Apoptosis induced by death receptors. Pharm Acta Helv. 74(2–3):281–286. doi:10.1016/s0031-6865(99)00038-2. PMID:10812970.
   PubMedGoogle Scholar
• Sarvothaman S, Undi RB, Pasupuleti SR, Gutti U, Gutti RK. 2015. Apoptosis: role in myeloid cell development. Blood Res. 50(2):73–79. doi:10.5045/br.2015.50.2.73. PMID:26157776.
   PubMedGoogle Scholar
• Ghobrial IM, Witzig TE, Adjei AA. 2005. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 55(3):178–194. doi:10.3322/canjclin.55.3.178. PMID:15890640.
   PubMed Web of Science ®Google Scholar
• Reed JC. 1997. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol. 34(4 Suppl 5):9–19. PMID:9408956.
   PubMed Web of Science ®Google Scholar
• Cleary ML, Smith SD, Sklar J. 1986. Cloning and structural analysis of cDnas for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell. 47(1):19–28. doi:10.1016/0092-8674(86)90362-4. PMID:2875799.
   PubMed Web of Science ®Google Scholar
• Chipuk JE, Green DR. 2008. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends in cell biology. Trends Cell Biol. 18(4):157–164. doi:10.1016/j.tcb.2008.01.007. PMID:18314333.
   PubMed Web of Science ®Google Scholar
• Rong YP, Bultynck G, Aromolaran AS, Zhong F, Parys JB, De Smedt H, Mignery GA, Roderick HL, Bootman MD, Distelhorst CW. 2009. The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor. Proc Natl Acad Sci U S A. 106(34):14397–14402. doi:10.1073/pnas.0907555106. PMID:19706527.
   PubMed Web of Science ®Google Scholar
• Uprety D, Adjei AAK. 2020. KRAS: from undruggable to a druggable Cancer Target. Cancer Treat Rev. 89(102070):102070. doi:10.1016/j.ctrv.2020.102070. PMID:32711246.
   PubMedGoogle Scholar
• McCormick F. 2016. K-Ras protein as a drug target. J Mol Med. 94(3):253–258. doi:10.1007/s00109-016-1382-7. PMID:26960760.
   PubMed Web of Science ®Google Scholar
• Wang Y, Deng M, Chen Q, Li Y, Guo X, Shi P, He L, Xie S, Yu L, Zhang H, et al. 2019. Apatinib exerts anti-tumor activity to non-Hodgkin lymphoma by inhibition of the Ras pathway. Eur J Pharmacol. 843(145):145–153. doi:10.1016/j.ejphar.2018.11.012. PMID:30423319
   PubMedGoogle Scholar
• Mendes J, Goncalves AC, Alves R, Jorge J, Pires A, Ribeiro A, Sarmento-Ribeiro AB. 2016. L744,832 and Everolimus induce Cytotoxic and Cytostatic effects in non-Hodgkin Lymphoma cells. Pathol Oncol Res. 22(2):301–309MID:26545383. doi:10.1007/s12253-015-9998-4.
   PubMed Web of Science ®Google Scholar
• Barry DM, Koo Y, Norden PR, Wylie LA, Xu K, Wichaidit C, Azizoglu DB, Zheng Y, Cobb MH, Davis GE, et al. 2016. Rasip1-mediated Rho GTPase signaling regulates blood vessel Tubulogenesis via Nonmuscle Myosin II. Circ Res. 119(7):810–826. doi:10.1161/CIRCRESAHA.116.309094. PMID:27486147
   PubMed Web of Science ®Google Scholar
• Chen CY, Faller DV. 1996. Phosphorylation of Bcl-2 protein and association with p21ras in Ras-induced apoptosis. J Biol Chem. 271(5):2376–2379MID:8576193. doi:10.1074/jbc.271.5.2376.
   PubMed Web of Science ®Google Scholar
• Kinoshita T, Yokota T, Arai K, Miyajima A. 1995. Regulation of Bcl-2 expression by oncogenic Ras protein in hematopoietic cells. Oncogene. 10(11):2207–2212. PMID:7784065.
   PubMed Web of Science ®Google Scholar